TA106 Hepatitis C - peginterferon alfa and ribavirin: review decision - December 2013 information
History
Documents created during the development process.
Background information
-
-
TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
TA106 Hepatitis C - peginterferon alfa and ribavirin: review proposal - October 2013 information
-
TA106 Hepatitis C - peginterferon alfa and ribavirin: - Appendix A - provisional matrix of stakeholders
-
-
TA106 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013
-
-
-
Review decision - March 2008: table of comments
-
Review decision - March 2008: table of comments (PDF 135 KB)
-
-
-
Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Final appraisal determination
Response to consultee and commentator comments on the ACD
-
Response to consultee and commentator comments on the ACD
-
Response to consultee and commentator comments on the ACD (PDF 90 KB)
Consultee and commentator comments on the ACD
-
Consultee and commentator comments on the ACD
-
Association of Nurses in Substance Abuse
-
-
British Society of Gastroenterology
-
-
Department of Health Development Agency
-
-
Foundation of Liver Research
-
-
Haemophilia Society
-
-
Hepatitis C Trust
-
-
MRC Clinical Trials Unit
-
-
NHS Quality Improvement Scotland
-
-
Roche Products Limited
-
-
Royal College of General Practitioners
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
-
Schering-Plough Ltd
-
-
Welsh Assembly Government
-
-
Welsh Assembly Government attachment
-
Expert comments on the ACD
-
Foster
-
Hepatitis C (mild) - interferon alfa (pegylated and non-pegylated) and ribavirin (review): Appraisal consultation document
Final scope
-
Final scope
-
Evaluation Report
-
Evaluation Report
-
Hepatitis C - peginterferon alfa and ribavirin: assessment report
-
Hepatitis C - peginterferon alfa and ribavirin: assessment report (PDF 1.21 MB)
-
Overview
-
-
Consultee and commentator comments on the assessment report
-
Royal College of Pathologists (2)
-
-
Schering Plough Ltd
-
-
CPAP ACD - Consultee and commentator comments: Royal College of Nursing
-
CPAP ACD - Consultee and commentator comments: Royal College of Nursing (PDF 12 KB)
-
Roche Products Ltd
-
-
NHS Quality Improvement Scotland
-
-
MRC Clinical Trials Unit
-
-
Mainliners
-
-
Haemophilia Alliance and UK Haemophilia Centre
-
-
British Society of Gastroenterology
-
-
British Association for the Study of the Liver
-
-
Manufacturer submissions (executive summary only)
-
Schering-Plough Ltd (2)
-
-
Roche Products Ltd (2)
-
-
Non manufacturer submissions
-
Royal College of Pathologists
-
-
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: Appraisal consultation - Royal College of Physicians
-
-
Royal College of Nursing (2)
-
-
Hepatitis C Trust
-
-
Haemophilia Society
-
-
Expert written personal statements
-
Morris
-
-
Maulayah
-
-
Gore
-
-
Foster
-
Final Protocol
-
Final Protocol
-
Response to consultee and commentator comments on the draft scope
-
Response to consultee and commentator comments on the draft scope
-
Response to consultee and commentator comments on the draft scope (PDF 41 KB)
Response to consultee and commentator comments on the provisional matrix of consultees and commentators
-
Response to consultee and commentator comments on the provisional matrix of consultees and commentators
-
Archive Draft scope
-
Archive Draft scope
-
Archive Provisional matrix of consultees and commentators
-
Archive Provisional matrix of consultees and commentators
-
Archive Provisional matrix of consultees and commentators (PDF 30 KB)